CRL

1. Business profile & competitive position

Charles River Laboratories International, Inc. is classified in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. Companies in this industry typically sit upstream of drug commercialization, providing outsourced testing, research services, analytical support, and diagnostics-related work to pharmaceutical, biotechnology, and academic customers rather than manufacturing finished therapeutics. A business in this segment would normally rely on recurring client relationships, long-term contracts, and the operating leverage of fixed laboratory capacity to build a durable competitive position.

The current financial figures, however, do not point to a business earning excess returns on that model. CRL’s trailing net margin is negative 6.0%, and its return on equity is negative 7.7%. A negative net margin means the company is losing roughly six cents on every dollar of revenue at the bottom line, while a negative ROE means management is currently destroying equity capital rather than compounding it. The beta of 1.40 also signals that the stock has been more volatile than the broader market, consistent with investors actively debating when—or whether—the business can return to profitable, above-cost returns on capital.

2. Financial posture

CRL’s current market capitalization is $12.9 billion. The stock’s trailing P/E ratio is negative 55.3, so the conventional multiple framework does not apply; a negative P/E simply reflects negative trailing earnings, not a standard valuation ceiling or floor. The same underlying picture is captured by the negative 6.0% net margin and the negative 7.7% ROE, both of which confirm the company has been losing money on a trailing basis.

Against that fundamental backdrop, the stock’s technical snapshot is worth watching. CRL closed at $267.49, roughly 22.9% above its 50-day exponential moving average of $217.69. The RSI reading of 76.2 is above the 70 level technicians commonly associate with an overbought condition. With a beta of 1.40, the stock has historically moved about 40% more than the overall market on a beta basis, so the combination of negative trailing profitability and a technically extended price produces both a high-stakes turnaround setup and elevated near-term volatility risk.

3. Macro & geopolitical exposure

Because CRL operates under Healthcare / Medical – Diagnostics & Research, its macro exposures are those that affect outsourced laboratory, testing, and research-service providers. Regulatory oversight is a primary factor: FDA, EMA, and comparable global agencies set standards for good laboratory practice, diagnostic quality, and—where live biological models are involved—animal welfare and import/export rules. Any tightening of those standards can raise compliance costs or limit cross-border research flows.

Funding cycles also matter. Government research budgets, including NIH outlays, directly influence demand for outsourced research and testing services. The industry is sensitive to biopharma R&D budgets, which shrink when capital markets tighten and early-stage projects are delayed or canceled. Trade and geopolitics can disrupt supplies of reagents, specialized equipment, and biological materials, while currency translation affects revenue booked outside the United States. Finally, pricing pressure from healthcare payors on diagnostics services can compress margins across the peer group.

4. Recent developments

Recent news flow is dominated by CRL’s second-quarter 2026 results. On Aug. 5, 2026, Seeking Alpha published the full Q2 2026 earnings call transcript. The same day, Zacks reported that CRL Q2 earnings and revenues topped estimates, management raised its 2026 view, and the stock was higher in pre-market trading. The actual Q2 EPS came in at $3.02 versus the $2.77 estimate, a 9% positive surprise.

On Aug. 6, 2026, MarketBeat published highlights from the Q2 earnings call, and 247wallst.com included Charles River among Thursday’s top Wall Street analyst research calls, alongside AppLovin, Global Payments, HubSpot, and others. The clustering of analyst attention on Aug. 6 reflects the typical post-earnings review cycle, with the Street digesting management’s upgraded 2026 guidance and the latest quarterly beat.

5. Earnings behavior & post-earnings drift

CRL’s earnings consistency has been striking. Over the last eight reported quarters, the company beat the estimate every time, for a 100% beat rate, and the average earnings surprise was 9.2%. Despite that unblemished beat record, the stock has not reliably drifted higher after the prints. The average 5-day price change following earnings across those same eight quarters is negative 1.37%, classified as a “down” post-earnings drift.

The last four reported quarters illustrate that divergence. After the Aug. 5, 2026 report, the stock rose 1.84% the next session but recorded 0% change over the following five trading days. The May 7, 2026 quarter produced actual EPS of $2.06 versus an estimate of $1.96, yet the stock fell 2.23% the next day and 12.42% over the next five days. The Feb. 18, 2026 quarter was the exception, with actual EPS of $2.39 versus $2.33, a 3.95% next-day gain, and a 6.05% five-day gain. The Nov. 5, 2025 quarter delivered a $2.43 actual versus $2.32 estimate beat, a 1.9% next-day move, and a 2.27% five-day gain. That pattern suggests the market frequently prices in strong execution ahead of the report, leaving the stock vulnerable to profit-taking even after a beat. The next scheduled report is Nov. 4, 2026, before the open, with the current consensus EPS estimate at $3.05.

For a deeper dive into how analysts, hedge funds, and institutional models currently view CRL’s setup, see the full institutional verdict on the platform. It aggregates the non-consensus view, model revisions, and ownership flows behind the stock’s recent price action.